Androgen levels during adjuvant endocrine therapy in postmenopausal breast cancer patients

References

• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687–717
   PubMed Web of Science ®Google Scholar
• Lao Romera J, Puertolas Hernandez T J, Pelaez Fernandez I, et al. Update on adjuvant hormonal treatment of early breast cancer. Adv Ther 2011;28(Suppl 6):1–18
   PubMedGoogle Scholar
• Baumgart J, Nilsson K, Stavreus-Evers A, et al. Urogenital disorders in women with adjuvant endocrine therapy after early breast cancer. Am J Obstet Gynecol 2011;204:26 e21–7
   PubMed Web of Science ®Google Scholar
• Baumgart J, Nilsson K, Evers AS, Kallak TK, Poromaa IS. Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer. Menopause 2013;20:162–8
   PubMed Web of Science ®Google Scholar
• Becker T, Lipscombe L, Narod S, Simmons C, Anderson GM, Rochon PA. Systematic review of bone health in older women treated with aromatase inhibitors for early-stage breast cancer. J Am Geriatr Soc 2012;60:1761–7
   PubMed Web of Science ®Google Scholar
• Younus M, Kissner M, Reich L, Wallis N. Putting the cardiovascular safety of aromatase inhibitors in patients with early breast cancer into perspective: a systematic review of the literature. Drug Saf 2011;34:1125–49
   PubMed Web of Science ®Google Scholar
• Batalo M, Nagaiah G, Abraham J. Cognitive dysfunction in postmenopausal breast cancer patients on aromatase inhibitors. Expert Rev Anticancer Ther 2011;11:1277–82
   PubMed Web of Science ®Google Scholar
• Dowsett M, Cuzick J, Howell A, Jackson I. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the ‘Arimidex and tamoxifen alone or in combination’ (ATAC) trial. Br J Cancer 2001;85:317–24
   PubMed Web of Science ®Google Scholar
• Geisler J, Haynes B, Anker G, Dowsett M, Lonning PE. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 2002;20:751–7
   PubMed Web of Science ®Google Scholar
• Kunovac Kallak T, Baumgart J, Stavreus Evers A, et al. Higher than expected estradiol levels in aromatase inhibitor-treated, postmenopausal breast cancer patients. Climacteric 2012;15:473–80
   PubMed Web of Science ®Google Scholar
• Rossi E, Morabito A, Di Rella F, et al. Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial. J Clin Oncol 2009;27:3192–7
   PubMed Web of Science ®Google Scholar
• Hadji P, Kauka A, Bauer T, Tams J, Hasenburg A, Kieback DG. Effects of exemestane and tamoxifen on hormone levels within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German substudy. Climacteric 2012;15:460–6
   PubMed Web of Science ®Google Scholar
• Ingle JN, Buzdar AU, Schaid DJ, et al. Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer. Cancer Res 2010;70:3278–86
   PubMed Web of Science ®Google Scholar
• Kushnir MM, Rockwood AL, Roberts WL, et al. Development and performance evaluation of a tandem mass spectrometry assay for 4 adrenal steroids. Clin Chem 2006;52:1559–67
   PubMed Web of Science ®Google Scholar
• Kushnir MM, Neilson R, Roberts WL, Rockwood AL. Cortisol and cortisone analysis in serum and plasma by atmospheric pressure photoionization tandem mass spectrometry. Clin Biochem 2004;37:357–62
   PubMed Web of Science ®Google Scholar
• Kushnir MM, Blamires T, Rockwood AL, et al. Liquid chromatography-tandem mass spectrometry assay for androstenedione, dehydroepiandrosterone, and testosterone with pediatric and adult reference intervals. Clin Chem 2010; 56:1138–47
   PubMed Web of Science ®Google Scholar
• Naessen T, Sjogren U, Bergquist J, Larsson M, Lind L, Kushnir MM. Endogenous steroids measured by high-specificity liquid chromatography-tandem mass spectrometry and prevalent cardiovascular disease in 70-year-old men and women. J Clin Endocrinol Metab 2010;95:1889–97
   PubMed Web of Science ®Google Scholar
• Kushnir MM, Rockwood AL, Bergquist J. Liquid chromatography-tandem mass spectrometry applications in endocrinology. Mass Spectrom Rev 2010;29:480–502
   PubMed Web of Science ®Google Scholar
• Lonning PE, Johannessen DC, Lien EA, Ekse D, Fotsis T, Adlercreutz H. Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients. J Steroid Biochem Mol Biol 1995; 52:491–6
   PubMed Web of Science ®Google Scholar
• Kostoglou-Athanassiou I, Ntalles K, Gogas J, et al. Sex hormones in postmenopausal women with breast cancer on tamoxifen. Horm Res 1997;47:116–20
   PubMed Web of Science ®Google Scholar
• Dowsett M, Folkerd E, Doody D, Haynes B. The biology of steroid hormones and endocrine treatment of breast cancer. Breast 2005;14:452–7
   PubMed Web of Science ®Google Scholar
• Sowers MF, Zheng H, McConnell D, Nan B, Karvonen- Gutierrez CA, Randolph JF Jr. Testosterone, sex hormone- binding globulin and free androgen index among adult women: chronological and ovarian aging. Hum Reprod 2009;24: 2276–85
   PubMed Web of Science ®Google Scholar
• Pugeat M, Moulin P, Cousin P, et al. Interrelations between sex hormone-binding globulin (SHBG), plasma lipoproteins and cardiovascular risk. J Steroid Biochem Mol Biol 1995;53: 567–72
   PubMed Web of Science ®Google Scholar
• Haffner SM, Katz MS, Stern MP, Dunn JF. Association of decreased sex hormone binding globulin and cardiovascular risk factors. Arteriosclerosis 1989;9:136–43
   PubMedGoogle Scholar
• Rexrode KM, Manson JE, Lee IM, et al. Sex hormone levels and risk of cardiovascular events in postmenopausal women. Circulation 2003;108:1688–93
   PubMed Web of Science ®Google Scholar
• Sutton-Tyrrell K, Wildman RP, Matthews KA, et al. Sex- hormone-binding globulin and the free androgen index are related to cardiovascular risk factors in multiethnic premenopausal and perimenopausal women enrolled in the Study of Women Across the Nation (SWAN). Circulation 2005;111: 1242–9
   PubMed Web of Science ®Google Scholar
• Baglietto L, English DR, Hopper JL, et al. Circulating steroid hormone concentrations in postmenopausal women in relation to body size and composition. Breast Cancer Res Treat 2009; 115:171–9
   PubMed Web of Science ®Google Scholar
• Key TJ, Appleby PN, Reeves GK, et al. Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer 2011;105:709–22
   PubMed Web of Science ®Google Scholar
• Falk RT, Gentzschein E, Stanczyk FZ, et al. Sex steroid hormone levels in breast adipose tissue and serum in postmenopausal women. Breast Cancer Res Treat 2012;131:287–94
   PubMed Web of Science ®Google Scholar
• Levin J, Markham MJ, Greenwald ES, et al. Effect of tamoxifen treatment on cortisol metabolism and the course of the disease in advanced breast cancer. Cancer 1981;47:1394–7
   PubMed Web of Science ®Google Scholar
• Wilking N, Carlstrom K, Skoldefors H, Theve NO, Wallgren A. Effects of tamoxifen on the serum levels of oestrogens and adrenocortical steroids in postmenopausal breast cancer patients. Acta Chir Scand 1982;148:345–9
   PubMedGoogle Scholar
• Kailajarvi M, Ahokoski O, Virtanen A, Salminen E, Irjala K. Early effects of adjuvant tamoxifen therapy on serum hormones, proteins and lipids. Anticancer Res 2000;20:1323–7
   PubMed Web of Science ®Google Scholar
• Tominaga T, Adachi I, Sasaki Y, et al. Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer. Ann Oncol 2003;14:62–70
   PubMed Web of Science ®Google Scholar
• Bisagni G, Cocconi G, Scaglione F, Fraschini F, Pfister C, Trunet PF. Letrozole, a new oral non-steroidal aromastase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study. Ann Oncol 1996;7:99–102
   PubMed Web of Science ®Google Scholar
• Sieri S, Krogh V, Bolelli G, et al. Sex hormone levels, breast cancer risk, and cancer receptor status in postmenopausal women: the ORDET cohort. Cancer Epidemiol Biomarkers Prev 2009;18:169–76
   PubMed Web of Science ®Google Scholar